Gt Biopharma Stock Price Prediction

GTBP Stock  USD 4.43  0.06  1.37%   
As of today, the RSI of GT Biopharma's share price is approaching 49. This usually indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling GT Biopharma, making its price go up or down.

Oversold Vs Overbought

49

 
Oversold
 
Overbought
GT Biopharma stock price prediction is an act of determining the future value of GT Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of GT Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of GT Biopharma and does not consider all of the tangible or intangible factors available from GT Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with GT Biopharma, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting GT Biopharma's stock price prediction:
EPS Estimate Next Quarter
(0.10)
EPS Estimate Current Year
(10.80)
Wall Street Target Price
150
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of GT Biopharma based on different types of headlines from major news networks to social media. The GTBP stock price prediction module provides an analysis of price elasticity to changes in media outlook on GT Biopharma over a specific investment horizon. Using GT Biopharma hype-based prediction, you can estimate the value of GT Biopharma from the perspective of GT Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards GT Biopharma using GT Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards GTBP using crowd psychology based on the activity and movement of GT Biopharma's stock price.

GT Biopharma Implied Volatility

    
  0.0  
GT Biopharma's implied volatility exposes the market's sentiment of GT Biopharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GT Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GT Biopharma stock will not fluctuate a lot when GT Biopharma's options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in GT Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in GT Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying GTBP because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

GT Biopharma after-hype prediction price

    
  USD 4.35  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out GT Biopharma Basic Forecasting Models to cross-verify your projections.
To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GT Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.234.6210.62
Details
1 Analysts
Consensus
LowTargetHigh
4.555.005.55
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-2.7-2.7-2.7
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as GT Biopharma. Your research has to be compared to or analyzed against GT Biopharma's peers to derive any actionable benefits. When done correctly, GT Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in GT Biopharma.

GT Biopharma After-Hype Price Prediction Density Analysis

As far as predicting the price of GT Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in GT Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of GT Biopharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

GT Biopharma Estimiated After-Hype Price Volatility

In the context of predicting GT Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on GT Biopharma's historical news coverage. GT Biopharma's after-hype downside and upside margins for the prediction period are 0.22 and 10.35, respectively. We have considered GT Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
4.43
4.35
After-hype Price
10.35
Upside
GT Biopharma is risky at this time. Analysis and calculation of next after-hype price of GT Biopharma is based on 3 months time horizon.

GT Biopharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as GT Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GT Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with GT Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.70 
5.95
  0.02 
  0.14 
2 Events / Month
3 Events / Month
In a few days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
4.43
4.35
0.46 
19,833  
Notes

GT Biopharma Hype Timeline

GT Biopharma is currently traded for 4.43. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.14. GTBP is forecasted to decline in value after the next headline, with the price expected to drop to 4.35. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.46%, whereas the daily expected return is currently at -0.7%. The volatility of related hype on GT Biopharma is about 3070.97%, with the expected price after the next announcement by competition of 4.57. About 13.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. GT Biopharma recorded a loss per share of 9.0. The entity last dividend was issued on the 21st of August 2017. The firm had 1:30 split on the 5th of February 2024. Given the investment horizon of 90 days the next forecasted press release will be in a few days.
Check out GT Biopharma Basic Forecasting Models to cross-verify your projections.
To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.

GT Biopharma Related Hype Analysis

Having access to credible news sources related to GT Biopharma's direct competition is more important than ever and may enhance your ability to predict GT Biopharma's future price movements. Getting to know how GT Biopharma rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how GT Biopharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
SUMSummit Materials(0.19)12 per month 1.79  0.04  3.28 (3.66) 8.86 
GETYGetty Images Holdings(0.39)9 per month 0.00 (0.11) 6.17 (8.04) 25.51 
DADTFDataDot Technology Limited 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
SPNSSapiens International 0.42 6 per month 1.83  0.01  2.30 (2.81) 7.17 
FALFFFalcon Metals Limited 0.00 0 per month 0.00 (0.06) 0.00  0.00  17.65 
QTWOQ2 Holdings 0.46 10 per month 1.86  0.08  3.62 (3.37) 13.27 
CTGOContango ORE 1.25 9 per month 3.88  0.03  8.08 (5.84) 22.37 
PGEZFGroup Ten Metals 0.00 0 per month 0.00 (0.06) 9.09 (9.09) 19.09 

GT Biopharma Additional Predictive Modules

Most predictive techniques to examine GTBP price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for GTBP using various technical indicators. When you analyze GTBP charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About GT Biopharma Predictive Indicators

The successful prediction of GT Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as GT Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of GT Biopharma based on analysis of GT Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to GT Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to GT Biopharma's related companies.
 2023 2024 (projected)
Days Of Sales Outstanding35.7154.84
Days Of Inventory Outstanding61.0586.22

Story Coverage note for GT Biopharma

The number of cover stories for GT Biopharma depends on current market conditions and GT Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that GT Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about GT Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

GT Biopharma Short Properties

GT Biopharma's future price predictability will typically decrease when GT Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of GT Biopharma often depends not only on the future outlook of the potential GT Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GT Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.3 B
Cash And Short Term Investments14 M
When determining whether GT Biopharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GTBP Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Gt Biopharma Stock. Highlighted below are key reports to facilitate an investment decision about Gt Biopharma Stock:
Check out GT Biopharma Basic Forecasting Models to cross-verify your projections.
To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for GTBP Stock analysis

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.00)
Return On Assets
(0.55)
Return On Equity
(0.79)
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.